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Background: The COVID-19 pandemic has disrupted routine hospital services globally. This study
estimated the total number of adult elective operations that would be cancelled worldwide during the
12 weeks of peak disruption due to COVID-19.
Methods: A global expert response study was conducted to elicit projections for the proportion of
elective surgery that would be cancelled or postponed during the 12 weeks of peak disruption. A Bayesian
𝛃-regression model was used to estimate 12-week cancellation rates for 190 countries. Elective surgical
case-mix data, stratified by specialty and indication (surgery for cancer versus benign disease), were
determined. This case mix was applied to country-level surgical volumes. The 12-week cancellation rates
were then applied to these figures to calculate the total number of cancelled operations.
Results: The best estimate was that 28 404 603 operations would be cancelled or postponed during the
peak 12 weeks of disruption due to COVID-19 (2 367 050 operations per week). Most would be operations
for benign disease (90⋅2 per cent, 25 638 922 of 28 404 603). The overall 12-week cancellation rate would
be 72⋅3 per cent. Globally, 81⋅7 per cent of operations for benign conditions (25 638 922 of 31 378 062),
37⋅7 per cent of cancer operations (2 324 070 of 6 162 311) and 25⋅4 per cent of elective caesarean sections
(441 611 of 1 735 483) would be cancelled or postponed. If countries increased their normal surgical
volume by 20 per cent after the pandemic, it would take a median of 45 weeks to clear the backlog of
operations resulting from COVID-19 disruption.
Conclusion: A very large number of operations will be cancelled or postponed owing to disruption
caused by COVID-19. Governments should mitigate against this major burden on patients by developing
recovery plans and implementing strategies to restore surgical activity safely.
∗Members of the COVIDSurg Collaborative are co-authors of this study and are listed in Appendix S1 (supporting
information)
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Introduction
The COVID-19 pandemic has led to major disrup-
tion of routine hospital services globally1. During the
pandemic hospitals have reduced elective surgery in
the interests of patient safety and supporting the wider
response2–4. Reducing elective activities protects patients
from in-hospital viral transmission and associated postop-
erative pulmonary complications. This preserves personal
protective equipment supplies to be prioritized for the care
of patients with COVID-19, and releases ward and critical
care beds for surges in such patients. It also enables recov-
ery areas in theatre suites to be repurposed as overflow
ICUs. Surgeons and theatres teams may be redeployed to
support other critical areas of the hospital.
Cancelling elective surgery on this scale will have a
substantial impact on patients and cumulative, potentially
devastating, consequences for health systems worldwide5.
Delaying time-sensitive elective operations, such as can-
cer or transplant surgery, may lead to deteriorating health,
worsening quality of life, and unnecessary deaths6–8. When
hospitals resume elective activities, patients are likely to
be prioritized by clinical urgency9, resulting in lengthen-
ing delays for patients with benign but potentially dis-
abling conditions where there may be less of a perceived
time impact. This will lead to a deterioration in population
health, productivity and a substantial societal cost.
Worldwide cancellations in elective surgery are currently
unquantified10,11. Few countries have access to real-time
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Fig. 1 Flow chart of methodology
Projections for proportions of elective cancer surgery,
benign surgery and obstetric procedures that will be
cancelled during the peak 12 months of disruption owing
to COVID-19 elicited from expert response study
Country-level surgical volume data and modelled cancellation rates were used to calculate totals for adult elective operations
cancelled during the peak 12 weeks of disruption owing to COVID-19, and stratified by World Bank region, World Bank
country income group and specialty
Data from expert response study fed in to Bayesian
β-regression model to estimate cancellation rates for
elective cancer surgery, benign disease surgery and
obstetrics for 190 countries
Cancellation rates for elective surgery by country Absolute volumes of elective surgery by country
Case-mix estimates refined based on surgeons’ estimates
from the expert response study for the proportion of
colorectal, head and neck, gynaecological, plastic, upper
gastrointestinal and urological procedures performed
for cancer
Elective surgical case mix (colorectal, head and neck,
obstetric and gynaecological, orthopaedic, plastic, upper
gastrointestinal, urological, and other surgery) determined
for each HDI quintile based on data collected across 64
countries by the Surgical Outcomes Studies
Case-mix estimates and previous figures for overall
surgical volume12 used to calculate absolute volumes of
adult elective surgery performed per country by specialty
HDI, Human Development Index.
data, and even those that do may experience delays in this
information being released owing to pressures on health
systems. Estimating country-level estimates will provide
the best possible baseline data to inform planning for post-
pandemic surgical recovery. This study aimed to estimate
the total number of elective operations that would be can-
celled or postponed worldwide during the 12 weeks of peak
disruption of hospital services owing to COVID-19.
Methods
The study methodology is summarized in Fig. 1. First,
an expert response study was undertaken to elicit sur-
geons’ projections of the proportion of elective surgery that
would be cancelled during the peak 12 weeks of disruption
owing to COVID-19. These data were fed into a Bayesian
β-regression model to estimate 12-week cancellation rates
for elective surgery for 190 countries. Second, elective sur-
gical case mix was determined for each Human Develop-
ment Index (HDI) quintile using data from the Surgical
Outcomes Studies and the expert response study. This case
mix was applied to existing figures for overall country-level
surgical volume to calculate expected specialty-specific sur-
gical volumes for 190 countries. Finally, these surgical vol-
ume figures and the 12-week cancellation rate estimates
were used to calculate total numbers of cancelled opera-
tions by specialty and country.
All 193 United Nations member countries were included
in this study except Liechtenstein, North Korea and Soma-
lia, as no surgical volume data were available for these
three countries12. At present, the only region to have recov-
ered from a large-scale SARS-CoV-2 outbreak is Hubei
Province in China. Wuhan, the capital of Hubei, was in
lockdown for 76 days (23 January 2020 to 8 April 2020).
Therefore, the current best estimate for the duration of dis-
ruption to health systems caused by COVID-19 is around
12 weeks. This is consistent with advice that hospitals
should plan to suspend non-urgent elective surgery for at
least 12 weeks4.
The secondary outcomes were total number of cancelled
operations stratified by World Bank region (Europe and
Central Asia, East Asia and Pacific, Latin America and
the Caribbean, North America, Middle East and North
Africa, South Asia, Sub-Saharan Africa), World Bank coun-
try income group (high, upper–middle, lower–middle,
low), and surgical specialty. Specialty-specific cancellation
totals were calculated for surgical specialties accounting for
5 per cent or more of the global surgical case mix (Table S1,
supporting information). This included colorectal, head
and neck, gynaecological, orthopaedic, obstetric, plastics,
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Table 1 Best estimates of cancelled operations over a 12-week









Colorectal 1 353 952 486 563 35⋅9
Gynaecology 834 839 328 505 39⋅3
Head and neck 959 190 373 603 38⋅9
Plastics 505 294 178 362 35⋅3
Upper gastrointestinal and
hepatobiliary
1 258 862 498 885 39⋅6
Urology 1 250 175 458 151 36⋅6
Benign surgery
Colorectal 1 201 825 976 992 81⋅3
Gynaecology 2 665 361 2 175 774 81⋅6
Head and neck 4 845 604 3 950 551 81⋅5
Orthopaedics 7 677 515 6 295 041 82⋅0
Plastics 933 822 764 033 81⋅8
Upper gastrointestinal and
hepatobiliary
2 728 786 2 223 194 81⋅5
Urology 3 051 523 2 492 604 81⋅7
Other 8 273 626 6 760 731 81⋅7
Obstetrics 1 735 483 441 611 25⋅4
Total 39 275 857 28 404 603 72⋅3
*Surgical volume at full capacity (no cancellations).
upper gastrointestinal (including hepatobiliary surgery)
and urological surgery. Colorectal, head and neck, gynae-
cological, plastics, upper gastrointestinal and urological
surgery were further stratified into operations performed
for cancer versus benign pathology. Orthopaedic surgery
was not stratified in this way as cancer accounts for a
very small proportion of orthopaedic operations. Special-
ties that individually account for under 5 per cent of surgi-
cal case mix were pooled into an ‘other surgery’ category,
including breast surgery, cardiac surgery, neurosurgery,
thoracic surgery and vascular surgery. Therefore, a total of
15 specialty groups were included in this study (Table 1).
Twelve-week elective surgery cancellation rates
Senior surgeons were invited to participate in an expert
response study to elicit their projections for the proportion
of elective surgery that would be cancelled during the peak
12 weeks of disruption owing to COVID-19. Surgeons
were contacted through the global CovidSurg network and
asked to enter their estimates into an online database. The
questionnaire was open from 20 to 30 March 2020.
Experts were asked to provide estimates for each of
the 15 specialty groups included in this study. For each
specialty group, experts provided their best estimate (the
most likely 12-week cancellation rate), as well as a lower
bound estimate (the lowest possible cancellation rate) and
an upper bound estimate (the highest possible cancellation
rate). If the SARS-CoV-2 outbreak had resolved at the
experts’ hospital, they were asked to report actual rates of
cancelled surgery due to the outbreak. If the outbreak was
ongoing, experts were asked to project likely cancellation
rates going forward. If the experts’ hospital had not yet
experienced a SARS-CoV-2 outbreak, they were asked to
estimate what would happen in the event of an outbreak.
After the expert response study questionnaire had closed,
responses were matched by hospital and, where there was
more than one expert participating per hospital, median
values for each data point were calculated, so that there
was one consolidated response per hospital. Overall median
values for the best estimate and upper/lower bounds were
then calculated for each participating country for cancer
surgery, surgery for benign disease and obstetric (elective
caesarean section) operations.
A Bayesian β-regression model was developed with 2018
HDI as a predictor, in order to establish 12-week cancel-
lation rate estimates for all 190 countries included in the
study (Table S2, supporting information). HDI is a com-
posite index of life expectancy, education and per-capita
income indicators, and its relationship with surgical out-
comes has been validated previously13,14.
Non-informative priors were used with sensitivity ana-
lyses done on alternative priors and different chain ini-
tiation points or chain lengths. A restricted cubic spline
transformation was applied to the continuous represen-
tation of the HDI rank (rank 1 being the most devel-
oped country and rank 190 the least developed) to account
for potential non-linearity. This was substituted into the
final β-regression model and posterior predictions were
made for each HDI rank. The model was fitted for the
best estimates and lower/upper bounds for cancer surgery,
surgery for benign disease and obstetric (caesarean section)
operations.
Surgical case mix
The best available global data on surgical case mix are from
the African Surgical Outcomes Study, European Surgi-
cal Outcomes Study and International Surgical Outcomes
Study15–17. These were prospective cohort studies that cap-
tured all adults undergoing surgery in participating facili-
ties, providing case-mix data for a total of 102 539 patients
across 64 countries. No comparable global case-mix data
exist for paediatric surgery, so this study was limited to
adults.
Raw data from the three Surgical Outcomes Studies were
pooled to estimate case mix by HDI quintile (Table S2, sup-
porting information). First, the case mix was determined
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according to urgency: elective versus emergency. Next,
within elective surgery the case mix was stratified by spe-
cialty. To determine cancer versus benign surgical case
mix, the expert response study participants were asked
to estimate the proportions of colorectal, head and neck,
gynaecological, plastics, upper gastrointestinal and uro-
logical operations performed in their hospitals for cancer.
Hospital-level results were then pooled by HDI quintile
to calculate median proportions of cancer surgery for each
specialty.
Surgical volume
A previous report12 identified total country surgical vol-
ume for 72 countries (presented as point estimates) and
modelled estimates for a further 120 countries (presented
as confidence intervals). As only overall total (paediatric
surgery) country volumes were available, population
age-structure data from the World Bank were used to
estimate total adult surgical volume for each country.
Adults were defined as people age 15 years and above,
consistent with age categories used for population data by
the World Bank.
Country-level surgical volumes for each of the 15 spe-
cialty groups included in this study were calculated based
on the country-specific adult surgical volume and case mix
for the appropriate HDI quintile. For the best estimate
of total cancellations, the point estimate (if provided) or
the midpoint of the confidence interval for country-level
surgical volume was used to calculate specialty-specific
country-level surgical volume.
Totals for cancelled surgery
Country-level surgical volume data and modelled 12-week
cancellation rates were used to calculate specialty
group-specific totals for adult elective operations can-
celled during the peak 12 weeks of disruption. The best
estimate for the number of cancelled operations was based
on the modelled best estimates for 12-week cancellation
rates.
Surgical recovery
The time it would take countries to clear the backlog of
operations resulting from 12 weeks of disruption owing
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Table 2 Weekly totals for best estimates of cancelled operations, by country
Weekly total operations cancelled Data by country
<1000 Albania (567), Andorra (41), Antigua and Barbuda (54), Bahamas, The (280), Bahrain (514), Barbados (193), Belize
(57), Benin (157), Bhutan (103), Botswana (792), Brunei Darussalam (249), Burkina Faso (237), Burundi (110),
Cabo Verde (49), Cambodia (601), Cameroon (744), Central African Republic (32), Chad (29), Comoros (24),
Congo, Democratic Republic (642), Congo, Republic (155), Cyprus (347), Djibouti (45), Dominica (27), Equatorial
Guinea (211), Eritrea (78), Eswatini (195), Fiji (175), Gabon (242), The Gambia (30), Grenada (43), Guinea (141),
Guinea-Bissau (35), Guyana (93), Haiti (305), Honduras (974), Iceland (297), Jamaica (964), Kiribati (7), Kyrgyz
Republic (877), Lao People’s Democratic Republic (192), Lesotho (115), Liberia (168), Luxembourg (564),
Madagascar (231), Malawi (283), Maldives (237), Mali (347), Malta (554), Marshall Islands (16), Mauritania (116),
Mauritius (260), Micronesia, Federated States (22), Monaco (32), Montenegro (268), Mozambique (370), Namibia
(497), Nauru (7), Nepal (277), Niger (206), North Macedonia (711), Palau (15), Papua New Guinea (338), Rwanda
(349), Samoa (13), San Marino (16), Sao Tome and Principe (18), Senegal (267), Seychelles (232), Sierra Leone
(110), Solomon Islands (55), South Sudan (135), St Kitts and Nevis (33), St Lucia (76), St Vincent and the
Grenadines (36), Suriname (243), Tajikistan (680), Tanzania (808), Timor-Leste (48), Togo (137), Tonga (26), Trinidad
and Tobago (892), Tuvalu (4), Uganda (890), Vanuatu (15), Yemen, Republic (188), Zambia (418), Zimbabwe (810)
1000–9999 Afghanistan (1048), Angola (1612), Armenia (1124), Azerbaijan (1556), Bangladesh (2671), Bolivia (1094), Bosnia and
Herzegovina (1625), Bulgaria (5109), Costa Rica (1734), Cote d’Ivoire (1153), Croatia (2086), Cuba (5578), Czech
Republic (6531), Denmark (5622), Dominican Republic (3934), Ecuador (2012), Egypt, Arab Republic (9055), El
Salvador (1200), Estonia (1255), Ethiopia (1124), Finland (6053), Georgia (1868), Ghana (1212), Greece (7492),
Guatemala (1119), Iraq (3420), Ireland (1376), Israel (3766), Jordan (1839), Kazakhstan (7339), Kenya (1780),
Kuwait (2593), Latvia (3565), Lebanon (2717), Libya (2060), Lithuania (2945), Moldova (1564), Mongolia (1283),
Morocco (1302), Myanmar (1674), New Zealand (2721), Nicaragua (1351), Nigeria (9543), Norway (5370), Oman
(1005), Pakistan (3746), Panama (2409), Paraguay (2211), Peru (7478), Portugal (8885), Qatar (1933), Romania
(9135), Saudi Arabia (9410), Serbia (3476), Singapore (4418), Slovak Republic (4644), Slovenia (1524), Sri Lanka
(3509), Sudan (3485), Switzerland (9162), Syrian Arab Republic (1697), Tunisia (3501), Turkmenistan (1208),
United Arab Emirates (6402), Uruguay (2292), Uzbekistan (6988), Vietnam (7110)
10 000–49 999 Algeria (12 870), Argentina (27 088), Austria (11 967), Belarus (17 569), Belgium (22 660), Canada (32 881), Chile
(11 696), Hungary (13 959), India (48 728), Indonesia (31 050), Iran, Islamic Republic (32 099), Korea, Republic
(17 267), Malaysia (12 891), Mexico (15 315), Netherlands (15 847), Philippines (13 593), Poland (22 656), South
Africa (12 795), Spain (45 449), Sweden (14 588), Thailand (18 332), Ukraine (21 943), UK (43 307), Venezuela, RB
(17 234)
50 000–99 999 Australia (67 149), France (58 708), Germany (75 730), Italy (50 552), Russian Federation (93 688), Turkey (82 002)
≥100 000 Brazil (247 444), China (326 177), Colombia (113 082), Japan (113 324), USA (343 670)
Values in parentheses are weekly total of cancelled operations for each country.
to COVID-19 was estimated. It was assumed that can-
celled obstetric (caesarean section) operations would not
need to be rescheduled after the pandemic. Therefore, the
time taken to clear country-level backlogs of operations for
benign disease and cancer was based on country-level base-
line volumes of surgery for these conditions. The number
of whole or part weeks needed to clear these backlogs was
calculated based on 10, 20 and 30 per cent increases in base-
line surgical volume.
Sensitivity analyses
An estimate for the minimum number of operations likely
to be cancelled was based on the lowest likely baseline sur-
gical volume (the lower bounds for total surgical volume
estimates where provided) and the modelled lower bounds
for 12-week cancellation rates. An estimate for the maxi-
mum number of operations likely to be cancelled was based
on the highest likely baseline surgical volume (the upper
bounds for total surgical volume estimates where provided)
and modelled upper bounds for 12-week cancellation rates.
Analyses were done using R version 3.6.3 and rstan (the
R interface to the statistical inference language Stan) and




From a total of 538 submissions to the expert response
study (Fig. S1, supporting information), data were available
for 359 hospitals in 71 countries (Table S3, supporting infor-
mation). Proportions of surgery projected to be cancelled
were consistently estimated to be higher for benign condi-
tions than for obstetrics (elective caesarean sections). Pro-
portions of cancer surgery projected to be cancelled were
lower in the most developed countries compared with the
least developed ones (Fig. S2, supporting information).
Based on the Bayesian β-regression model, best estimates
for country-level 12-week cancellation rates for cancer
surgery ranged from 23⋅4 to 77⋅1 per cent, whereas they
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High income 11 803 371 (83⋅6) 937 740 (30⋅3) 89 073 (20⋅1) 12 830 185 (72⋅7)
East Asia and Pacific 2 276 604 (84⋅6) 167 830 (28⋅7) 17 271 (21⋅7) 2 461 704 (73⋅4)
Europe and Central Asia 4 895 041 (83⋅7) 384 630 (30) 39 106 (20⋅9) 5 318 777 (72⋅7)
Latin America and the Caribbean 188 143 (81⋅7) 22 331 (38⋅7) 3718 (23⋅4) 214 192 (70⋅5)
Middle East and North Africa 284 896 (83) 26 142 (33⋅9) 3076 (23⋅3) 314 114 (72⋅4)
North America 4 156 253 (83⋅1) 336 510 (31) 25 855 (17⋅5) 4 518 619 (72⋅4)
Sub-Saharan Africa 2434 (81) 297 (39⋅5) 47 (22⋅7) 2778 (70)
Upper–middle income 11 824 165 (80⋅4) 1 171 864 (43⋅4) 254 374 (26⋅4) 13 250 403 (72⋅1)
East Asia and Pacific 3 836 777 (79⋅6) 370 906 (47⋅8) 83 989 (27⋅9) 4 291 672 (72⋅8)
Europe and Central Asia 2 402 694 (81⋅5) 277 144 (37⋅8) 47 108 (23⋅2) 2 726 946 (70⋅2)
Latin America and the Caribbean 4 811 770 (80⋅6) 436 109 (43⋅6) 101 324 (26⋅9) 5 349 203 (72⋅8)
Middle East and North Africa 579 884 (80⋅4) 67 302 (44⋅5) 12 885 (24⋅9) 660 070 (71⋅4)
South Asia 38 931 (82⋅1) 5227 (45⋅1) 798 (24⋅6) 44 957 (72⋅2)
Sub-Saharan Africa 154 110 (77⋅7) 15 176 (55⋅6) 8270 (28⋅4) 177 555 (69⋅7)
Lower–middle income 1 906 718 (78⋅8) 200 315 (56⋅8) 86 875 (29⋅5) 2 193 909 (71⋅6)
East Asia and Pacific 591 840 (79⋅5) 63 188 (55⋅3) 16 827 (28⋅6) 671 855 (73⋅2)
Europe and Central Asia 338 114 (80⋅8) 31 754 (48⋅3) 6595 (24⋅4) 376 463 (73⋅7)
Latin America and the Caribbean 47 844 (76⋅7) 4839 (57⋅8) 2749 (28⋅8) 55 433 (69⋅1)
Middle East and North Africa 144 904 (77⋅7) 14 644 (56) 7282 (29⋅9) 166 830 (70⋅4)
South Asia 571 190 (79) 58 633 (60⋅1) 33 156 (28⋅9) 662 980 (70⋅9)
Sub-Saharan Africa 212 826 (75⋅1) 27 257 (67⋅8) 20 266 (33⋅7) 260 349 (67⋅8)
Low income 104 668 (75⋅1) 14 150 (70⋅2) 11 289 (34⋅6) 130 106 (67⋅7)
Europe and Central Asia 7055 (78⋅6) 689 (57⋅2) 418 (30⋅4) 8162 (70⋅7)
Latin America and the Caribbean 2900 (72⋅1) 405 (69⋅1) 355 (36⋅5) 3660 (65⋅6)
Middle East and North Africa 18 259 (77⋅3) 2415 (70⋅2) 1941 (34) 22 615 (69)
South Asia 12 872 (75⋅2) 1710 (69⋅8) 1311 (34⋅4) 15 892 (68)
Sub-Saharan Africa 63 582 (74⋅2) 8931 (71⋅6) 7264 (35⋅1) 79 777 (67⋅1)
Values in parentheses are cancellation rate during the 12 weeks of peak disruption owing to COVID-19. There are some small inconsistencies between
totals due to differences in how figures have been rounded.
































Elective operations performed during pandemic
Elective operations cancelled during pandemic
Elective operations performed are those that are projected not to be cancelled during the 12 weeks of peak disruption owing to COVID-19.
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Values are best estimate (range). There are some small inconsistencies between totals due to differences in how figures have been rounded.
ranged from 71⋅2 to 87⋅4 per cent for surgery for benign
conditions, and from 17⋅4 to 37⋅8 per cent for obstetrics
(Fig. 2; Table S4, supporting information).
Surgical volume
The best estimate for cancellations was based on a global
annual adult elective surgical volume of 170 195 382 oper-
ations (Fig. S3, supporting information). Details of surgical
case mix are provided in Tables S5–S8 and Figs S4–S7 (sup-
porting information).
Total cancellations
The best estimate was that 28 404 603 operations would be
cancelled or postponed globally during the peak 12 weeks
of the COVID-19 pandemic. Worldwide 2 367 050 opera-
tions would be cancelled per week, with 11 countries can-
celling more than 50 000 operations per week (Table 2).
Most of the cancelled or postponed operations were esti-
mated to be for benign disease (90⋅2 per cent, 25 638 922
of 28 404 603), followed by cancer (8⋅2 per cent, 2 324 070
of 28 404 603) and obstetrics (1⋅6 per cent, 441 611 of
28 404 603) (Table 1). The best estimate was that the
global 12-week cancellation rates would be 72⋅3 per
cent (28 404 603 of 39 275 857) overall, 81⋅7 per cent
(25 638 922 of 31 378 062) for benign disease surgery, 37⋅7
per cent (2 324 070 of 6 162 311) for cancer surgery and
25⋅4 per cent (441 611 of 1 735 483) for obstetrics (Table 3).
Overall, 12-week cancellation rates by World Bank
region would range from 68⋅3 to 73⋅0 per cent. The
most cancellations were projected to take place in Europe
and Central Asia (8 430 348 procedures) and the least in
Sub-Saharan Africa (520 459) (Fig. 3 and Table 4), reflect-
ing the low baseline surgical volume there. Country-level
totals stratified by specialty are presented in Table S9
(supporting information).
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Surgical recovery
Based on a 20 per cent increase in baseline surgical volume,
it was estimated that it would take countries a median of
45 (range 43–48) weeks to clear the backlog of operations
resulting from 12 weeks of disruption due to COVID-19
(Table S10, supporting information). If baseline surgical
volume were increased by 10 per cent, it would take coun-
tries a median of 90 (86–95) weeks to clear the backlog,
whereas with a 30 per cent increase in baseline surgical vol-
ume this would take a median of 30 (29–32) weeks.
Sensitivity analyses
The minimum estimate was that 19 849 153 operations
would be cancelled worldwide during the 12 weeks of
peak disruption due to COVID-19 (1 654 096 per week),
representing a 61⋅1 per cent 12-week cancellation rate
(19 849 153 of 32 488 250). The maximum estimate was
that 43 945 672 operations would be cancelled during
the peak 12 weeks (3 662 139 per week), representing a
12-week cancellation rate of 86⋅2 per cent (43 945 672 of
50 960 625).
Discussion
This study has demonstrated the major burden of can-
celled elective surgery due to the COVID-19 pandemic.
Although a similar proportion of surgery will be cancelled
across different country income settings and geographi-
cal regions, the greatest number of cancellations will be
in upper–middle-income countries. Cancer surgery will
be prioritized in most settings, with most cancellations
relating to surgery for benign conditions, most frequently
orthopaedics.
The risks of exposing patients to perioperative
SARS-CoV-2 infection by performing surgery during
outbreaks are high, but must be weighed against the risks
of protracted treatment delays. Given that many health
systems already lack sufficient capacity to meet the need for
surgery18, the impact of cancellations will be cumulative,
adding to existing waiting lists. Governments will need to
fund substantial increases in baseline surgical volume to
clear backlogs, but this is likely to be costly. For example,
based on an average cost of £4000 per operation, it would
cost over £2 billion to clear the UK’s backlog.
There is a risk that delayed treatment of benign condi-
tions as a result of pandemic-related cancellations will lead
to deterioration in individual patients’ conditions, increas-
ing disability and reducing their ability to work. This
will lead to lead to substantial societal costs, particularly
in low–middle income countries (LMICs) where catas-
trophic expenditure relating to surgical disease can lead to
impoverishment19,20.
This study has several limitations. Although estimates
were based on the best available global surgical data, several
assumptions were required. As the COVID-19 pandemic
is ongoing, it was necessary for the expert response study
participants to project forward their estimates for 12-week
cancellation rates. Participants in countries where the pan-
demic was in its earliest stages, such as in Sub-Saharan
Africa, may have had to base their estimates on experi-
ence in previous emergencies, rather than the specific cir-
cumstances of COVID-19. The uncertainty around these
estimates was captured by recording both lower and upper
bounds, as well as best estimates for 12-week cancellation
rates. Surgical case mix was based principally on snapshot
cohort studies that collected data across 64 countries15–17.
Given the barriers to participation in research, particularly
in LMICs21, it is unknown how representative these data
are of the global case mix. Most countries do not publish
surgical volume data, so this study relied on previous esti-
mates of country-level surgical volume.
The eventual geographical extent and intensity of the
pandemic is currently unknown, but it is likely that most
countries will be affected22–24. The country-level figures
can be used to produce estimates of cancellations per week,
allowing policymakers to adjust estimates according to the
predicted duration of local outbreaks. Prediction of the
impact of COVID-19 on elective surgery in local commu-
nities can inform local planning and resource prioritization.
Postpandemic surgical recovery planning should antic-
ipate the possibility of repeat waves of SARS-CoV-2
infection25, leading to additional periods of cancella-
tion of elective surgery. Therefore, strategies to safely
maintain surgical volume during and immediately after
SARS-CoV-2 outbreaks should be explored. For example,
time-sensitive surgery, such as cancer resection, can be
performed in designated non-COVID-19 units that do
not treat patients with COVID-19. Although the optimal
organization of such surgical units is unknown, it is likely
that they should carefully select low-risk patients who are
unlikely to require intensive care and can be operated safely
in satellite units. Both patients and staff will require rigor-
ous screening to reduce the risks of cross-infection. Surgi-
cal recovery plans should also consider that an immediate
return to high-volume surgery may not be possible. For
example, adaptations to operating theatres, such as installa-
tion of negative pressure flow systems, may need to be expe-
dited to reduce the delay to resumption of normal activity.
Future research should be prioritized to identify strate-
gies to mitigate the risk of operating in COVID-19
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environments, so that cancellations are minimized. For
example, although ongoing trials are testing treatments for
COVID-1926–28, large randomized trials are also needed
to test therapies to prevent postoperative COVID-19
pulmonary complications.
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